Laboratory diagnosis of Clostridium difficile disease  by Delmée, M.
UPDATE
Laboratory diagnosis of Clostridium difficile disease
M. Delme´e
Microbiology Unit, Universite´ Catholique de Louvain, Brussels, Belgium
The laboratory diagnosis of Clostridium difficile-associated disease (CDAD) is based on culture and toxin detection
in fecal specimens. Culture is performed on a commercially available selective media. C. difficile colony
morphology is typical when viewed under a dissecting microscope. Definitive identification is best obtained by
gas liquid chromatography. Culture is very sensitive but, when used alone without toxin testing, it leads to low
specificity and misdiagnosis of CDAD when high rates of asymptomatic carriage exist. Toxin detection by a
tissue culture cytotoxin assay followed by neutralisation with specific antiserum is often considered the standard.
However, this approach lacks sensitivity and has not detected up to 30% of patients with confirmed CDAD.
Multiple enzyme immunoassays (EIAs) have been introduced by various manufacturers for the detection of toxin
A alone or for both toxins A and B. Some of these are designed to give results in less than 1 h. Comparative studies
of EIA kits reported that the sensitivity and specificity are slightly lower than cytotoxin assays. Toxigenic culture
tests C. difficile isolates for toxin production: colonies isolated on selective media are tested for in-vitro toxin
production either by a cytotoxicity assay or by direct EIA. It has higher sensitivity than the cytotoxicity assay and
equivalent specificity. In the routine laboratory, culture and toxin detection should be performed on every
specimen and, in culture-positive and fecal toxin-negative cases, toxigenic cultures should be performed on
isolated colonies.
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INTRODUCTION
Clostridium difficile is a Gram-positive anaerobic sporulating
bacillus which has been known since 1978 to cause a severe
disease of the colon called pseudomembranous colitis. One of
the most remarkable characteristics of this disease is that, in
almost all cases, it occurs following antibiotic therapy. The
pathogenesis of C. difficile-associated disease (CDAD) is
very particular and allows a better understanding of the cir-
cumstances in which the clinician should make a diagnosis
(Figure 1).
PATHOGENESIS OF CDAD
The very first condition to induce pathology is a disturbance of
the normal intestinal flora. The gut flora act as a colonisation
barrier which, in a normal state, protects against C. difficile. This
barrier is compromised when the flora is disturbed. The main
factor able to induce such a disturbance is antibiotic therapy.
Almost all compounds have been implicated, in particular the
broad-spectrum cephalosporins and all molecules active on
anaerobic flora.
There are several other circumstances which have been
reported to induce such a disturbance, such as cancer che-
motherapy or antacid treatment, but these account for a min-
ority of cases. Finally, neonates who do not yet have constituted
flora, are very often colonised by C. difficile but, for several
poorly understood reasons, they remain asymptomatic in most
cases.
Colonisation by C. difficile constitutes the second step of the
disease. Intestinal carriage of C. difficile is estimated to be very
low, between 1 and 2% and, hence, colonisation from an
endogenous source is relatively rare. The main concern with
this bacteria is that, once hospitalised patients get diarrhea, they
very rapidly contaminate their environment with spores which
are very resistant and may persist for months, thus creating the
potential for a hospital outbreak. At present, C. difficile is
considered to be the most common cause of diarrhea in
hospitalised patients [1].
In the case of colonisation, C. difficile usually produces two
toxins called A and B which are the main virulence factors. Not
all strains produce these toxins. One of the most interesting
features of CDAD is that there is a very wide range of clinical
presentations; even in the case of toxin production, a patient
may remain asymptomatic, or exhibit only mild diarrhea,
whereas others may exhibit severe pseudomembranous colitis
or even fulminant life-threatening colitis.
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The factors that influence the severity of the symptoms are
now better understood. For instance, the age of the patient is an
important factor; most of the severe cases are seen in patients
over 65 or 70 years. However, as demonstrated in several recent
publications, what now appears to be the main factor is the level
of the immune response in terms of circulating IgG or local IgA
against toxin A. Patients with severe symptoms have signifi-
cantly lower serum- and feces-specific antibody levels than
those with milder symptoms [2]. Moreover, a serum antibody
response to toxin A during an initial episode of CDAD is
associated with protection against recurrence [3]. It has also
been shown that, after colonisation of a patient by C. difficile,
there is an association between a systemic response to toxin A, as
evidenced by increased serum levels of IgG antibody against
toxin A, and asymptomatic carriage of C. difficile [4]. Therefore,
given this scheme, the main indication – but not the sole one –
for a bacteriological diagnosis of CDAD is diarrhea occuring in
elderly, hospitalised patients with a history of antibiotic therapy.
Several authors have advocated testing only for C. difficile in
cases of diarrhea occurring in patients hospitalised for more
than 3 days [5,6].
The clinical diagnosis of CDAD can be made by rectoscopy
or colonoscopy when classical pseudomembranes are seen. A
negative finding, however, does not rule out the diagnosis since
endoscopic diagnosis has a poor sensitivity. When a clinician
suspects CDAD, a laboratory confirmation should be requested
and a fecal specimen submitted.
L ABORATORY DIAGNOSIS
A laboratory diagnosis of CDAD is based on the isolation of the
pathogen in stool specimens by culture and by toxin detection,
which can be performed either by detection of a cytopathic
effect of a stool filtrate on cell lines or by a direct enzyme
immunoassay (EIA). The cytotoxin detection is advocated by
many authors, especially in the USA, as the standard diagnosis
but both culture and toxin detection are necessary to achieve an
optimal result.
Other indirect tests have been proposed previously, such as
direct gas liquid chromatography (GLC) on stool specimens,
latex agglutination or computed tomography scan, but these
approaches do not reach sufficient sensitivity and specificity
to be accepted unless they are used in addition to the other
tests.
For an optimal bacteriological diagnosis, only liquid stools
should be accepted, except in the case of an epidemiolo-
gical investigation. Due to a rapid loss of cytotoxin activity,
only fresh specimens should be processed and they should
be stored at 4 8C or less, in case tests cannot be performed
rapidly. Brazier reported complete inactivation of cytotoxin
in about 20% of samples sent through the post [7]. On
the other hand, cultures of C. difficile remain unaffected by
ambient storage due to sporulation. Repeated samples within
7 days of the initial request seem to give little useful informa-
tion [8].
Figure1 Pathogenesis ofClostridium difficile-associated diarrhea.
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CULTURE
Just after the discovery of the pathogenic role of C. difficile,
George et al. proposed a selective agar plate called CCFA
(cycloserine cefoxitin fructose agar) for the isolation from
stool specimens [9]. This medium is still used in most labora-
tories. The selective agents are cycloserine at a concentration
of 500 mg/L and cefoxitin at 16 mg/L. These concentra-
tions were reduced to 250 and 8 mg/L, respectively, in some
studies [10]. The original formulation included egg-yolk,
which may be replaced by blood. It is commercially available
from several companies. Stools are directly inoculated and
incubated in an anaerobic atmosphere for 48 h. Anaerobic
preincubation of the plate may improve the recovery rate as
well [11]. In our experience, the use of an Anoxomat system
(Mart Microbiology NV, Lichtenvoorde, Netherlands), which
allows an anaerobic atmosphere to be obtained in the jar
within 1 min, allows the plates to be read after only a 24 h
incubation.
Several modifications have been proposed to enhance the
sensitivity of the culture. Most are aimed at recovering more
spores and are more dedicated to epidemiological studies and
environmental cultures. Addition of pure sodium taurocholate
or cholate at a concentration of 1 g/L allows a better spore
germination [12] and is suitable for environmental cultures or in
cases of negative culture with positive fecal cytotoxin (see
below). The sodium salt of cholic acid is just as effective as
pure taurocholate in stimulating spore germination but is much
less expensive [7]. Pretreatment of stools with ethanol-shock
(equal volumes of ethanol and feces mixed for 1 h before
inoculation) has also been shown to increase the sensitivity
of culture [13].
It is worth saying that, in the vast majority of cases, the use of
a standard CCFA medium with a standard inoculation proce-
dure is quite satisfactory for diagnosis. Culture is the most
sensitive method but it is not very specific due to the possibility
of isolating non-toxigenic isolates. It is slow but allows strains to
be tested for toxigenicity; it is also the only way to carry out
epidemiological investigations.
Colonies of C. difficile are easily recognised on culture plates
due to their typical morphology (ground glass appearance)
when observed with binoculars. A yellow-green or chartreuse
fluorescence under ultraviolet illumination is another charac-
teristic of the colonies but this may vary with the medium
used. The typical odor (horse manure) is also an aid to identi-
fication. GLC of an agar plug around a suspected colony
is the best and easiest method for confirming identification.
C. difficile displays a typical GLC profile with large amounts
of butyric and iso-caproic acids. Such devices, however, are
not available in many laboratories. Individual biochemical
tests or anaerobic panels may also be used, as well as a somatic
antigen latex kit. Cross-reactions, however, have been
documented with this latter reagent. A direct EIA for toxin
A may also be used but then, of course, it will only recognise
toxigenic isolates. Production of proline-aminopeptidase by a
disc test has been proposed recently as a means of rapid
identification of C. difficile when it is used in conjunction with
the typical morphology of the colonies [14].
TOXIN DETECTION
Cytotoxin detection is often considered as the standard for
the diagnosis of C. difficile infections. This method consists of
inoculating a filtrate of a stool suspension into a cell culture and
observing a cytopathic effect as a consequence of disruption of
the cell cytoskeleton; which results in cell rounding in many cell
lines. The effect is mainly due to toxin B, which is 1000 times
more cytotoxic than toxin A.
Almost all cell lines commonly used in clinical microbiology
laboratories can be used to detect fecal cytotoxin: Vero, Hep2,
fibroblast, CHO or HeLa cells are the most common. Vero cell
lines are considered by many to be the most sensitive. A
suspension of 1 : 5 of the fecal sample is made in phosphate-
buffered saline and, after centrifugation, the supernatant is
filtered through a 0.2-mM filter. The filtrate is then inoculated
on the cell monolayer and the presence or absence of the
cytotoxic effect is observed after 24 and 48 h. In some of the
most severe clinical cases, typical rounding may be observed
after 4–6 h. Confirmation of the specificity is obtained by
repeating the test with the addition of a specific antiserum
directed against C. difficile or against C. sordellii, which shares the
same antigens.
The method has many advantages. It is sensitive and speci-
fic, and can detect other clostridial toxins. On the other hand, it
is relatively slow in comparison to EIA. In addition, non-
specific cytopathic effect (not neutralised by antiserum) may
be observed in about 2% of the cases, rendering any inter-
pretation impossible. The necessity of maintaining cell lines,
which is both time-consuming and expensive, especially if
only a small number of specimens are processed, is another
drawback.
For the last 10 years, there have been many EIAs on the
commercial market. Establishment of a complete list is difficult
since not all are available in every country. Most use monoclonal
antitoxin A antibodies, whereas a few are designed to detect
both toxins. Finally, in one of the latest kits, the detection of
toxin A is coupled with the detection of a glutamate dehy-
drogenase, a C. difficile-specific enzyme found in toxigenic as
well as in non-toxigenic isolates. The reason why kits detec-
ting both toxins have been developed is mainly because some
isolates from clinical cases have been shown to produce only
toxin B [15]. In our experience, such strains are very rarely
observed. In England, however, it has been found to account
for 3% of the strains referred to the reference laboratory
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for typing [16], and outbreaks have been described in Canada
[17]. Some kits are presented as individual panels, others as
96-well microplates. One of the main advantages of these
kits is their rapidity, since results can be obtained within
20 min.
There have been numerous publications regarding the per-
formances of the different kits. When compared to fecal
cytotoxin detection on cell lines, the different EIAs show a
slightly lower sensitivity. In our hands, cytotoxicity could be
detected in a 1/64 dilution of a positive fecal sample, although
only at half-dilution for most of the EIAs (unpublished results).
The same observations have been made in clinical studies
[18–23].
In several studies, toxigenic culture and detection of toxi-
genicity have been demonstrated as the most sensitive and
specific technique for the diagnosis of CDAD [18,22,24,25].
In this approach, culture of fecal specimens on CCFA is
followed by in vitro determination of the toxigenicity of the
positive colonies by the cytotoxin test or by EIA. Most com-
parisons of EIA kits against toxigenic culture have demonstrated
lower performances of EIAs.
One of the most recent kits, Triage C. difficile panel (Biosite
Diagnostics, San Diego, CA, USA), combines the detection of
toxin A and of glutamate dehydrogenase (GDH), an enzyme
which is produced by C. difficile. Although the sensitivity of
toxin A detection is within the same range of other kits (79.4%),
the addition of the GDH test allows an excellent negative
predictive value of an infection by C. difficile to be obtained
[26,27]. A negative result for both tests at the same time means
that the presence of a toxigenic strain of C. difficile can be
excluded with a reliability of 99.6% [27]. It may be used as a
rapid screening test to decide which stools need to be processed
further.
Although less sensitive, the EIAs provide same-day results and
can be used as a screening test. They may be useful in labora-
tories without tissue-culture facilities. They should always be
combined with culture and, when negative with a positive
culture, should be repeated by testing the strain isolated on the
plate.
MOLECULAR METHODS
Molecular methods for the diagnosis of CDAD have been
studied far less than those used to diagnose other infectious
diseases. This is probably due to the relatively satisfactory results
obtained with classical methods as described above, as well as to
the difficulty in applying such methods to fecal specimens
known to interfere with amplification procedures.
Several methods based on the PCR for amplifying part of the
toxin A gene have been effective in distinguishing toxigenic
from non-toxigenic isolates, but these approaches seem to have
few advantages over the routine laboratory methods.
Direct detection of C. difficile genes in fecal specimens have
been tested as well. Oligonucleotide probes designed to detect
toxin B have been used by Green et al. [28] with sensitivity and
specificity in the same range as EIAs. PCR using sets of primers
designed to detect toxin A or B have been tested on stools by
several authors [29–32]. The procedures usually comprise a
preliminary step to avoid inhibitory substances. So far, they have
been tested in small series of specimens and the results have not
shown any significant improvement when compared with the
classic methods.
CONCLUSIONS
During the last 15 years, our laboratory has received a total of
20 698 diarrheal stools from patients over 10 years old, for the
diagnosis of CDAD. The results of both fecal culture and
cytotoxin assay were negative in 17 731 cases (86%). Culture
was positive in 2622 cases (13%) but less than half of these
positive cultures (1,149) also had a positive fecal cytotoxin.
When testing culture-positive, cytotoxin-negative isolates, 852
(58%) were shown to be toxigenic strains in vitro. This means
that, performing the cytotoxin assay alone, 852 stools (4.1%)
with toxigenic strains would have been overlooked. In our
viewpoint, these observations justify the following scheme
for the routine bacteriological diagnosis of CDAD (Table 1);
culture and toxin detection (by cytotoxicity or by EIA) should
be performed on every specimen. When both tests are negative
Table1 Proposed scheme for the bacteriological diagnosis of CDAD
Initial tests on stools
Culture Fecal toxin Additional test Conclusion
  No CDAD
þ þ CDAD
þ  Strain in vitro toxigenicity
þ Probable CDAD
 Carriage of non-toxigenicC. difficile
 þ Repeated culture on CCFAþ taurocholate Probable CDAD
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(as in 87% of the cases), a diagnosis of CDAD is excluded. If
both are positive, a diagnosis of CDAD necessitates treat-
ment and the implementation of hospital hygiene prevention
measures.
When culture is positive but toxin remains negative, a direct
EIA test should be performed on several colonies picked
up directly on the culture plate and, hence, within 30 min it
is determined whether the strain is toxigenic or not. If the test
is negative, treatment for CDAD is not necessary. If the test is
positive, CDAD is very likely and the same measures as for a
direct positive test should be adopted. On the very few occa-
sions where culture is negative but there is a positive cytotoxin
test (0.2%), a control specimen is usually requested and the
culture repeated with a CCFA including taurocholate; a positive
result is usually obtained.
One could object that low carriage rates of toxigenic strains
with no detectable level of toxin might indicate carriage rather
than an infection. We believe, however, that patients with
diarrhea who are carriers of a toxigenic strain are likely to
contamine the environment; this reason alone justifies per-
forming the culture.
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